RNA-programmable endonuclease systems and their use in genome editing and other applications

US11578323B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• CRISPR THERAPEUTICS AG · CH

Inventors

• Andre COHNEN · Hasselsweiler, DE
• Moritz Schmidt · Cologne, DE
• Wayne Coco · Cologne, DE
• Ashish Gupta · Sunnyvale, US
• Jan Tebbe · Cologne, DE
• Cindy SCHULENBURG · Leverkusen, DE
• Christian Pitzler · Leverkusen, DE
• Michael Biag Gamalinda · Leverkusen, DE
• Sabine Jach · Leverkusen, DE
• Florian Richter · Mannheim, DE
• Anup Arumughan · Leverkusen, DE
• Corinna Saalwächter · Leverkusen, DE

Key dates

• Filing date: Dec 14, 2018
• Grant date: Feb 14, 2023
• Expiry date: Feb 27, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/80
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

Aspects of this invention inter alia relate to novel systems for targeting, editing or manipulating DNA in a cell, comprising one or more heterologous vector(s) encoding a SluCas9 nuclease from Staphylococcus lugdunensis or variants thereof, and one or more guide RNAs (gRNAs), or a SluCas9 nuclease or variant thereof and one or more gRNAs.